TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Mesoblast Limited ( (AU:MSB) ) has issued an announcement.
JPMorgan Chase & Co. and its affiliates have ceased to be substantial holders in Mesoblast Limited, a company involved in the development of regenerative medicine products. The change in their substantial holding status is due to various transactions involving securities lending, purchasing, and sales, as well as the rehypothecation of client securities. This shift in holdings may impact Mesoblast’s market perception and investor confidence, as JPMorgan’s involvement was significant in terms of voting securities.
The most recent analyst rating on (AU:MSB) stock is a Buy with a A$3.11 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
More about Mesoblast Limited
Average Trading Volume: 5,377,053
Technical Sentiment Signal: Buy
Current Market Cap: A$3.7B
See more insights into MSB stock on TipRanks’ Stock Analysis page.